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INTRODUCTION
Aortic valve (AoV) stenosis is a progressive disease associ-
ated with inflammation and calcium deposition on the valve
leaflets. Previous studies have suggested that cellular fac-
tors are involved in the different pathways that are related to
AoV inflammation and adverse remodelling. Studies have
shown that the most significant cellular factors involved in
AoV pathogenesis are the hepatocyte growth factor, vascu-
lar endothelial growth factor D, intercellular adhesion mole-
cule-1, tumour necrosis factor-, and interleukin-1 (Kim et
al., 2018). There are limited data on the role of cellular fac-
tors in the progression of AoV stenosis, and therefore our
aim was to identify new cellular factors that could serve as
significant biomarkers for AoV stenosis.
Chemerin can be involved in vascular disease complications
in different ways, such as a growth factor, chemokine and
as an adipokine (Kaur et al., 2018). Chemerin, as a growth
factor, has an effect on the activity of matrix metallopro-
teinases (MMPs), in particular MMP-9, thus causing growth
and remodelling of blood vessels, as well as endothelial cell
proliferation, migration, and angiogenesis (Heymans et al.,
2005). Chemerin also promotes the proliferation and migra-
tion of vascular smooth muscle cells, which may lead to
vascular structural remodelling (Kunimoto et al., 2015). As
a chemokine, chemerin promotes macrophage adhesion to
vascular cell adhesion molecule-1 and extracellular matrix
protein fibronectin. Chemerin also contributes to increased
intracellular Ca2+ concentration, activates pathways of nu-
clear factor-kappa () B and matrix activated protein kin-
ases in monocytes, macrophages, dendritic cells and endo-
thelial cells (Heymans et al., 2005). Many studies have
confirmed that chemerin has inflammatory functions, oppo-
site to that of the findings from Yamawaki and colleagues
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The aim of the present study was to evaluate plasma levels of chemerin, myeloperoxidase
(MPO), fibroblast growth factor-21 (FGF-21), thioredoxin reductase-1 (TrxR1), and matrix
metallopeptidase-9 (MMP-9) in acquired aortic valve (AoV) stenosis patients to determine correla-
tions between the studied cellular factors, and also clarify the predictive values of these factors as
biomarkers in AoV stenosis. AoV stenosis patients were classified into three groups: 17 patients
with mild AoV stenosis; 19 with moderate and 15 with severe AoV stenosis. Twenty-four subjects
without AoV stenosis were selected as a control group. Our findings suggest that AoV stenosis
might be associated with increased chemerin, TrxR1, MPO, and FGF-21 levels in plasma. Moreo-
ver, these factors and also MMP-9 already reached statistically significantly elevated levels in the
early stages of AoV stenosis, but MPO levels were more pronounced in patients with moderate
and severe AoV stenosis. Chemerin was correlated with all of the studied cytokines; TrxR1 and
MMP-9 were correlated with several other cellular factors. Our findings (by ROC analysis) sug-
gest that MPO and chemerin might serve as specific and sensitive biomarkers for AoV stenosis
without grading the severity, but, in relation to mild AoV stenosis, TrxR1, FGF-21, and MMP-9
also reached good or moderate levels as biomarkers. The cellular factors might serve as novel di-
agnostic and prognostic biomarkers in AoV stenosis patients, while chemerin and MPO may be
more powerful.
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(Yamawaki et al., 2015). Recent studies showed that
chemerin plays a critical role in the development of cardio-
vascular diseases, e.g., coronary atherosclerosis (Spiroglou
et al., 2010), acute coronary syndrome (Ji et al., 2014), aor-
tic atherosclerosis, and carotid stenosis (Kammerer et al.,
2018). Our previous study showed that the chemerin level is
increased in patients with AoV stenosis (Lurins et al.,
2018).
Chemerin significantly increases the production of reactive
oxygen species (ROS) in cells (Kunimoto et al., 2015). Oxi-
dative stress plays an important role in the development of
cardiovascular disorders (El Hadri et al., 2012; Chen et al.,
2017). Myeloperoxidase (MPO), a leukocyte-derived redox
enzyme, catalyses the formation of ROS and is an index of
oxidative stress (Couchie et al., 2017). It is interesting that
MPO exerts effects that are beyond its oxidative properties,
e.g. pro-inflammatory properties (van der Veen et al., 2009;
Nussbaum et al., 2013). Several types of tissue injuries and
chronic diseases, including cardiovascular diseases, are as-
sociated with MPO-derived oxidants (Khan et al., 2018).
Recent findings showed that MPO is highly expressed in
the AoV of AoV stenosis patients (Wada et al., 2013).
Other data suggest that endothelial dysfunction occurs
mainly due to increased MPO release (causing inflamma-
tion), which has impact primarily on integrity of the valve
rather than aortic structure (Ali et al., 2014). The pathobiol-
ogy of AoV stenosis is complex and involves multiple fea-
tures (Akahori et al., 2018), but there are very few pub-
lished data on the role of MPO.
Until recently, the heart was not traditionally considered as
a site of fibroblast growth factor-21 (FGF-21) production.
FGF-21 is produced by cardiac cells at significant levels
and acts as a cardiomyokine on the heart itself (Planavila et
al., 2015a; 2015b). FGF-21 has an ability to protect against
cardiac hypertrophy and cardiac inflammation (Planavila et
al., 2015b). Its concentration was observed to be associated
with increased cardiovascular risk and had a prognostic
value in cardiovascular outcomes (Lenart-Lipiñska et al.,
2015). Circulating FGF-21 levels are elevated in coronary
heart disease, atherosclerosis (Planavila et al., 2015), myo-
cardial ischemia, cardiac hypertrophy (Cheng et al., 2016)
and also, as our study showed, in AoV stenosis (Lurins et
al., 2018). Recent findings indicate that FGF-21 exerts car-
dioprotective effects, e.g., protects against cardiac hypertro-
phy and cardiac inflammation (Lenart-Lipiñska et al., 2015;
Planavila et al., 2015). Studies have shown that FGF-21
protects against oxidative stress, including regulation of
genes that are involved in antioxidant pathways, thus pre-
venting ROS production in cardiac cells (Planavila et al.,
2015a; 2015b).
The thioredoxin system is one of the main regulators for
protection against oxidative stress. The system consists of
thioredoxin-1, thioredoxin reductase-1 (TrxR1) and
NADPH and regulates the protein dithiol/disulphide balance
(El Hadri et al., 2012). TrxR1, a selenoenzyme, exerts not
only antioxidant, but also anti-inflammatory and antiapop-
totic properties (Chen et al., 2017; Couchie et al., 2017).
Previous studies have shown that TrxR1 is pivotal in
atherogenesis (Zhang et al., 2018), but there is almost no
study of its role in stenosis of the AoV.
AoV diseases are characterised by pathological remodelling
of valvular tissue (Fondard et al., 2005). Diseased AoV are
characterised by fibrosis and calcification, where fibrosis is
an early pathological change and related to AoV interstitial
cell proliferation and overproduction of extracellular matrix
proteins (Yao et al., 2017). Studies have shown that MMP-9
is a useful diagnostic marker for fibrosis and cardiac events
(Münch et al., 2016). The hallmarks of calcific AoV dis-
eases are the changes of the extracellular matrix, which lead
to increased leaflet stiffness and obstruction of left ventricu-
lar outflow. MMPs participate in numerous extracellular
matrix remodelling events, where MMP-9 may play a key
role in promotion of the fibrotic and procalcific remodelling
of the extracellular matrix (Perrotta et al., 2016).
The aim of the present study was to evaluate the plasma lev-
els of chemerin, MPO, FGF-21, TrxR1 and MMP-9 in ac-
quired AoV stenosis patients and also to determine correla-
tion between the study cellular factors, as well as clarify the
predictive values of these factors as biomarkers in AoV ste-
nosis.
MATERIALS AND METHODS
Study subjects. AoV stenosis patients were classified into
three groups according to the severity of the stenosis: 17 pa-
tients (mean ± SD: 71 ± 6 years) with mild AoV stenosis;
19 (72 ± 8) with moderate and 15 (65 ± 8) with severe AoV
stenosis according to the Guidelines on the Management of
Valvular Heart Disease 2012 of the European Society of
Cardiology (Vahanian et al., 2012). Twenty four subjects
(68 ± 9 years) without AoV stenosis (echocardiographically
approved) were selected as a control group. The study
groups were matched by age, sex, and body mass index. Pa-
tients who had evidence of bicuspid AoV and congenital or
rheumatic AoV stenosis were not included. Taking into ac-
count that some the studied cellular factors were adipokines,
exclusion criteria were obesity, diabetes mellitus, hypercho-
lesterolemia and hypertriglyceridemia. Other exclusion cri-
teria were smoking, arterial hypertension, coronary artery
disease, myocardial or cerebral infarction, peripheral vascu-
lar disease, thyroid dysfunction, acute inflammatory condi-
tion or chronic inflammatory states such as rheumatoid ar-
thritis, systemic lupus erythematosus, vasculitis,
inflammatory bowel disease, renal or liver diseases, or ma-
lignancies, and other diseases that are known to be associ-
ated with significant changes of cellular factors, including
surgery or trauma within the preceding 30 days. We did not
include patients who were taking COX-2 inhibitors,
nonsteroidal anti-inflammatory agents or corticosteroids, or
had been taking them within the preceding 30 days. All pa-
tients were included in the study during outpatient examina-
tions. All subjects gave their informed consent to the proto-
col, which was approved by the local Medical Ethics
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Committee of the Rîga Stradiòð University for biomedical
research.
AoV stenosis assessment. Patients were examined echocar-
diographically, and the data were archived using GE VIVID
7 Dimension and Philips IE 33, both from KPI Healthcare
(Yorba Linda, CA, USA). Each echocardiography examina-
tion was evaluated by two professionals. Patients with AoV
stenosis were subdivided into three groups depending on the
severity grade according to the echocardiography criteria:
aortic jet velocity (Vmax) (m/sec); mean pressure gradient,
PG (mmHg); aortic valve area, AVA (cm2) and indexed
AVA (cm2/m2). Data were graded as: severe: Vmax > 4
m/sec, PG > 40 mmHg, AVA < 1.0 cm2, indexed AVA <
0.6; moderate: Vmax 3.0–4.0 m/sec, PG 20–40 mmHg, AVA
1.0–1.5 cm2, indexed AVA 0.60–0.85; and mild: Vmax
2.5–2.9 m/sec, PG < 20 mmHg, AVA > 1.5 cm2, indexed
AVA > 0.85 (Vahanian et al., 2012).
Laboratory assays. Venous blood samples of the subjects
were collected after overnight fasting, centrifuged, and
stored at –80°C. Chemerin, MPO, FGF-21, TrxR1, and
MMP-9 were measured in plasma by ELISA method using
a TECAN Infinite 200 PRO multimode reader (Tecan
Group, Ltd., Mannedorf, Switzerland). Concentrations of
lipids, glucose, and other routine blood biomarkers were
analysed by standard methods.
Statistical analysis. To estimate the data distribution we
used the Lilliefors and Shapiro-Wilk's tests. Data were cal-
culated as the medians and interquartile ranges (IQR). Sta-
tistical differences between two groups were analysed by
the Mann-Whitney test and differences among four sub-
groups of the study assessed by the Kruskal–Wallis test. A
regression analysis was performed to evaluate the relations
between the study biomarkers. The performance of the
study biomarkers was assessed using receiver-operating
characteristic (ROC) curves, sensitivity, specificity, and
negative and positive predictive values. The p-value was re-
ported for the area under the curve (AUC) for the best cut-
off level. Diagnostic tests were assessed by this classifica-
tion: 0.90–1 = excellent; 0.80–0.90 = good; 0.70–0.80 =
fair; 0.60–0.70 = poor; and 0.50–0.60 = fail. All analyses
were performed using STATISTICA 10 software (StatSoft
Inc., USA).
RESULTS
Patients with AoV stenosis had a significantly higher
plasma level of chemerin compared to controls (57.24
(43.84–75.96) vs. 32.24 (31.14–42.18) ng/ml, p < 0.0001).
Interestingly, the chemerin level was highest in patients
with mild and moderate AoV stenosis (p < 0.001), but not
with severe AoV stenosis (p < 0.05) (Table 1).
Also, the level of MPO was significantly higher in patients
with AoV stenosis compared to controls (34.94
(28.69–40.50) vs. 27.12 (24.43–30.20) ng/ml, p < 0.0001).
Regarding MPO, patient subgroups showed slightly differ-
ent arrangement of levels than in the case of chemerin. Fig-
ure 1 shows that the greatest difference of MPO level was in
patients with moderate AoV stenosis (p < 0.0001), while
MPO was statistically significantly higher in patients with
severe AoV stenosis (p < 0.05 and p < 0.001) (Table 1).
Although the FGF-21 level was also higher in patients than
in the controls, its statistical significance was lower than
other cellular factors studied (367.77 (222.08–524.63) vs.
282.99 (132.58–386.43) ng/ml, p < 0.05), except MMP-9.
The FGF-21 level was significantly different only in pa-
tients with mild and severe AoV stenosis (p < 0.05 and p <
0.05) (Table 1).
A slightly more pronounced difference was observed be-
tween TrxR1 levels in patients with AoV stenosis and con-
trols compared to FGF-21 (25.10 (19.13–36.53) vs. 21.34
(17.48–23.36) ng/ml, p < 0.01). Figure 1 demonstrates that
the highest difference of TrxR1 levels is in patients with
mild AoV stenosis (p < 0.001), but in patients with moder-
ate AoV stenosis TrxR1 did not show significant differ-
ences from control subjects, however in patients with severe
AoV stenosis TrxR1 levels reached the levels of statistical
significance (p < 0.05).
The level of MMP-9 did not significantly differ in the pa-
tients with AoV stenosis compared to controls (2900
(2367–3593) vs. 2585 (2152–3037) ng/ml, p < 0.05), but
the MMP-9 level was significantly different in patients with
mild and severe AoV stenosis (p < 0.05 and p < 0.05) (Ta-
ble 1).
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T a b l e 1











Chemerin, ng/mg 32.24 (31.14– 42.18) 67.97** (45.33– 83.16) 57.94** (45.40– 76.00) 50.43* (35.22– 64.15) 0.0005
MPO, ng/mg 27.12 (24.43– 30.20) 27.86 (23.77– 40.34) 35.17*** (29.88– 40.01) 35.77** (28.46– 46.57) 0.002
FGF-21, pg/ml 282.99 (132.58– 386.43) 352.05* (310.28– 492.20) 309.38 (184.69– 593.18) 439.63* (287.25– 714.51) NS
TrxR1, ng/mg 21.34 (17.48– 23.36) 27.86** (23.77– 40.34) 21.07 (16.14– 27.49) 23.73* (19.13– 33.74) 0.002
MMP-9, pg/ml 2585.2 (2152.4– 3037.2) 3248.9* (2824.0– 3686.2) 2547.1 (2077.1– 2900.0) 2972.4* (2692.4– 3495.3) 0.032
Data are expressed as number (n), or median (IQR); AoV, aortic valve; MPO, myeloperoxidase; FGF, fibroblast growth factor; TrxR, thioredoxin reductase;
MMP, matrix metallopeptidase; NS, not significant (p > 0.05 compared to all group); *p < 0.05, **p < 0.01, ***p < 0.001 compared to control group.
We found several correlations between the study cellular
factors (Table 2). First of all, we found that chemerin sig-
nificantly correlated with all other studied cellular factors:
MPO (p = 0.006), FGF-21 (p = 0.006), TrxR1 (p = 0.0002)
and MMP-9 (p = 0.001). Furthermore we established close
correlation between MPO and TrxR1 (p = 0.008) as well as
between MPO and MMP-9 (p = 0.001). We also found sig-
nificant correlation between FGF-21 and TrxR1 (p = 0.031).
To evaluate the predictive values of the study cellular fac-
tors as biomarkers in AoV stenosis we used ROC analysis.
The analysis showed that chemerin is a moderate (fair) di-
agnostic marker in all AoV stenosis groups without grading
the severity (AUC = 0.786) (Fig. 1, Table 3). Also, the ROC
curve shows that chemerin is a specific and sensitive bio-
marker for mild AoV stenosis (AUC = 0.799) (Fig. 2, Table
4). However, MPO was a good diagnostic marker in all
AoV stenosis groups (AUC = 0.801), and was a moderate
diagnostic marker in mild AoV stenosis group (AUC =
0.723). FGF-21 was a poor diagnostic marker in all AoV
stenosis groups (AUC = 0.678), although in mild AoV
stenosis group it reached moderate level (AUC = 0.703).
TrxR1 was also a poor diagnostic marker in all AoV steno-
sis groups (AUC = 0.689), but showed a good level as a di-
agnostic marker in the mild AoV stenosis group (AUC =
0.841). Like the previous two cellular factors, MMP-9 was
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T a b l e 2
CORRELATION OF BIOMARKERS*
Chemerin MPO FGF-21 TrxR1 MMP-9
Chemerin –––
MPO r = 0.32;
p = 0.006
–––
FGF-21 r = 0.41;
p = 0.006
NS –––












Abbreviations see in Table 1. * data from all patients and controls; NS. not
significant.
T a b l e 3
CHARACTERISTICS OF ROC CURVES AS DIAGNOSTIC MARKERS




Area (AUC) Asymptotic 95% confidence interval
lower bound upper bound
MPO, ng/ml 0.801 0.704 0.897
TrxR1, ng/m 0.689 0.572 0.805
Chemerin, ng/ml 0.786 0.665 0.906
FGF-21, pg/m 0.678 0.551 0.806
MMP-9, pg/ml 0.632 0.505 0.758
Abbreviations see in Table 1. AUC, under the curve
T a b l e 4
CHARACTERISTICS OF ROC CURVES AS DIAGNOSTIC MARKERS




Area (AUC) Asymptotic 95% confidence interval
lower bound upper bound
MPO, ng/ml 0.723 0.556 0.890
TrxR1, ng/m 0.841 0.699 0.982
Chemerin, ng/ml 0.799 0.655 0.943
FGF-21, pg/m 0.703 0.541 0.865
MMP-9, pg/ml 0.733 0.561 0.905
Abbreviations see in Table 1. AUC, under the curve
Fig. 1. Receiver-operating characteristic (ROC) curves for chemerin,
myeloperoxidase (MPO), fibroblast growth factor-21 (FGF-21),
thioredoxin reductase 1 (TrxR1), and matrix metallopeptidase 9 (MMP-9)
as diagnostic markers of aortic valve (AoV) stenosis in the control group
vs. all stenosis groups.
Fig. 2. ROC curves for chemerin, MPO, FGF-21, TrxR1, and MMP-9 as
diagnostic markers of AoV stenosis in the control group vs. the mild AoV
stenosis group. Abbreviations see in Fig. 1.
a poor diagnostic marker in all AoV stenosis groups (AUC
= 0.632), but it reached a moderate level (AUC = 0.733) in
the mild AoV stenosis group.
DISSCUSION
The results showed that patients of our study already had
significantly increased levels of all circulating plasma cellu-
lar factors (excluding MPO) in the early stage of AoV
stenosis, which was most clearly expressed for chemerin
and TrxR1. In addition, the closest correlation is between
these two factors (p = 0.0002). Active inflammation pre-
vails at early stages of AoV stenosis and chemerin plays an
important role in endothelial inflammation, including in-
creasing endothelial cell adhesion molecule expression and
secretion (El Hadri et al., 2012). Interestingly, TrxR1 levels
increase at the same time. It is known that it not only exerts
antioxidants, but also anti-inflammatory properties (Chen et
al., 2017; Couchie et al., 2017). Moreover, it should be
noted that the ROC curve shows that chemerin and TrxR1
are specific and sensitive biomarkers directly for mild AoV
stenosis, but they are moderate and poor diagnostic markers
in all AoV stenosis groups, without grading the severity.
The level of statistical significance of chemerin levels be-
tween patients and the control subjects remained in the
moderate stage, but a slight decrease was observed in the
severe stage of the AoV stenosis patient group. This could
be due to the fact that chemerin also acts as a growth factor
and has an effect on activity of MMPs (Ali et al., 2014).
Levels of TrxR1, which is involved in the system for pro-
tection against oxidative stress (El Hadri et al., 2012), lost
statistical significance in the moderate stage, but it recov-
ered in the severe stage of AoV stenosis patient group.
MPO, which is as an index of oxidative stress (Couchie et
al., 2017), also had pronounced correlation with chemerin
(p = 0.006) as well as close and positive correlation with
TrxR1 in AoV stenosis patients and controls. MPO, unlike
TrxR1, reached the highest level in patients with moderate
(p < 0.001) and maintained high statistical significance in
severe AoV stenosis (AoV calcification stage) patients. This
AoV calcification is no longer considered as a simple pas-
sive process of calcium deposition but as a complex, regu-
lated process that also involves the extent of inflammatory
activation and oxidative stress especially in the early stages
of AoV stenosis where it first causes endothelial dysfunc-
tion and then affects other AoV cells (Akahori et al., 2018).
MPO is linked to both inflammation and oxidative stress
(Ali et al., 2014). MPO-derived oxidants contribute to tis-
sue damage in many diseases, especially those characterised
by inflammation (Nussbaum et al., 2013). MPO, unlike
TrxR1 and chemerin, was observed to be a specific and sen-
sitive (good) diagnostic marker in all AoV stenosis groups
without grading the severity.
It should be noted that there were many exclusion criteria
that are known to be associated with significant changes of
cellular factors and oxidative stress biomarkers; to exclude
atherosclerosis, the carotid intima-media thickness (Stein et
al., 2008) and ankle-brachial index were evaluated in AoV
stenosis patients. Therefore, it was interesting to find an in-
creased level of FGF-21 in the early stage (p < 0.05) and
also in the severe stage of AoV stenosis patients. Studies
have shown that FGF-21 is also produced by the heart and
exerts protective effects, and is involved in antioxidant
pathways (Planavila et al., 2015; Cheng et al., 2016).
FGF-21 was correlated with TrxR1 (an antioxidant bio-
marker) and chemerin (an inflammatory biomarker) in the
patients and controls of our study. FGF-21 was poor as a di-
agnostic marker in all AoV stenosis groups, but it reached a
moderate level in the mild stage of AoV stenosis group pa-
tients.
The MMP-9 level was similar to that of FGF-21, increasing
in the early stage (p < 0.05) and also in the severe stage of
AoV stenosis group patients. Considering that MMP-9 is in-
volved in the fibrotic and procalcific remodelling of the
extracellular matrix (Münch et al., 2016; Perrotta et al.,
2016), an increase in this level is expected in the severe
stage, but it is more difficult to explain its increase at an
early stage. One explanation might be that increased
chemerin stimulates the production of MMP-9 in this stage
of AoV stenosis (Kaur et al., 2018). MMP-9 was correlated
(p = 0.001) with chemerin (an inflammatory biomarker) and
MPO (an oxidant biomarker) in patients and controls of our
study. Similar to FGF-21, MMP-9 is a poor diagnostic
marker in all AoV stenosis groups, but it reached moderate
levels in the mild stage of AoV stenosis group patients.
The clinical value of individual biomarkers within the sin-
gle time points is limited. Hence, the future of biomarker
application in heart failure, including AoV stenosis, lies in
the multimarker panel strategy (Savic-Radojevic et al.,
2017). Regarding AoV stenosis, important biomarkers are
chemerin, FGF-21 and MMP-9, as well as oxidative stress
biomarkers: TrxR1 and MPO.
CONCLUSION
The findings suggest that AoV stenosis might be associated
with increased chemerin, TrxR1, MPO, and FGF-21 levels
in plasma (since all subclinical atherosclerotic sites in the
body cannot be completely excluded), moreover these cellu-
lar factors as well as MMP-9 already reached statistically
significant elevated levels at the early stages of AoV steno-
sis, but MPO levels were more pronounced in patients with
moderate and severe AoV stenosis. Chemerin was corre-
lated with all the study cellular factors; TrxR1 and MMP-9
were correlated with several other cellular factors. Our find-
ings (by the ROC analysis) suggest that MPO and chemerin
might serve as specific and sensitive biomarkers for AoV
stenosis without grading the severity, but in relation to mild
AoV stenosis, also TrxR1, FGF-21 and MMP-9 reached
good or moderate level as biomarkers. The cellular factors
might serve as novel diagnostic and prognostic biomarkers
in AoV stenosis patients, but chemerin and MPO may be
more powerful.
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JAUNO AORTAS VÂRSTUÏA STENOZES BIOMARÍIERU PROGNOSTISKÂ VÇRTÎBA
Pçtîjuma mçríis bija novçrtçt plazmas hemerîna, mieloperoksidâzes (MPO), fibroblastu augðanas faktora-21 (FGF-21), tioredoksîna
reduktâzes-1 (TrxR1) un matriksa metaloproteinâzes-9 (MMP-9) koncentrâcijas iegûtâs aortas vârstuïa (AoV) stenozes pacientiem, lai
novçrtçtu korelâcijas starp pçtîjumâ minçtajiem pçtîjuma râdîtâjiem un noskaidrotu ðo râdîtâju kâ biomaríieru prognostisko vçrtîbu. Tika
izveidotas trîs AoV pacientu grupas: 17 pacienti ar vieglu AoV, 19 ar vidçju un 15 ar smagu AoV, bet 24 indivîdi veidoja kontroles grupu.
Iegûtie rezultâti liecina, ka AoV stenoze ir saistîta ar hemerîna, TrxR1, MPO un FGF-21 koncentrâcijas palielinâjumu, turklât sasniedzot ðo
râdîtâju un arî MMP-9 koncentrâcijas palielinâjuma statistisko ticamîbu pret kontroles grupu jau vieglas AoV stenozes stadijâ, bet MPO
koncentrâcijas palielinâjums visvairâk bija izteikts pacientiem ar vidçju un smagu AoV stenozi. Hemerîns korelçja ar visiem pçtîjuma
râdîtâjiem, savukârt, TrxR1 un MMP-9 arî korelçja ar atseviðíiem râdîtâjiem. ROC (Receiver Operating Characteristic) lîkòu analîze
apliecinâja, ka MPO un hemerîns var kalpot kâ specifisks un jutîgs biomaríieris AoV stenozei neatkarîgi no AoV stadijas, bet, attiecîbâ uz
pacientiem ar vieglu AoV stadiju arî TrxR1, FGF-21 un MPO sevi apliecinâja kâ labas un vidçjas pakâpes biomaríieri. Visi pçtîjuma
râdîtâji var tikt izmantoti kâ jauni diagnostiski un prognostiski biomaríieri pacientiem ar AoV stenozi, bet hemerînam un MPO ir lielâka
prognostisko vçrtîba.
